RxDoctor Payments Data

Nichole Vanduyne, DO

Pulmonary Disease · Kansas City, MONPI 1992732556

Payments from drug & device makers

$2,280in general payments, 2019–2025

Across 118 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$375
  • AstraZeneca$263
  • GSK$243
  • Boehringer Ingelheim$194
  • Regeneron Healthcare Solutions, Inc.$189
  • Grifols USA, LLC$159
  • plus $856 from 23 others

What the payments were for

  • Food & beverage$2,280100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,280 in reported general payments places this provider in the 50th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$138,266
Medicare patients
278
Services billed
1,847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter220$171,294
XolairOmalizumab35$100,743
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr104$67,310
Breztri AerosphereBudesonide/Glycopyr/Formoterol75$58,680
Stiolto RespimatTiotropium Br/Olodaterol Hcl71$37,025
Breo ElliptaFluticasone/Vilanterol55$31,935
Spiriva RespimatTiotropium Bromide27$20,975
SymbicortBudesonide/Formoterol Fumarate22$11,069
Fluticasone-SalmeterolFluticasone Propion/Salmeterol74$8,901
ArexvyRsvpref3 Antigen/As01e/Pf28$7,698
Incruse ElliptaUmeclidinium Bromide11$6,555
Albuterol Sulfate HfaAlbuterol Sulfate168$3,721
Wixela InhubFluticasone Propion/Salmeterol40$3,363
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$1,821
Fluticasone Propionate125$1,605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy, Incruse Ellipta$243$284,792418 claims
AstraZenecaBreztri Aerosphere, Symbicort$263$69,74997 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$194$58,00098 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →